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ABSTRACT
The aim of this study was to evaluate the efﬁcacy and safety of caspofungin in patients treated in
Finland during the period 2001–2004. The medical records of 78 adult patients treated with caspofungin
in ﬁve major hospitals were reviewed retrospectively. Fifty-nine (76%) patients had proven invasive
fungal infection, of whom 22 (28%) had aspergillosis and 37 (47%) had candidiasis. Nineteen (24%)
patients were treated empirically; only 13 (17%) patients received caspofungin as primary therapy. A
favourable response was achieved in 52 (67%) patients. The response rate was 78% in patients with
candidiasis, and 50% in patients with aspergillosis. At the end of the study period, 40 (51%) patients
remained alive; of the 38 deaths, nine (24%) were caused by fungal infection. The response rates were
lower, although not signiﬁcantly, for patients with high (>20) vs. low (£20) Acute Physiology and
Chronic Health Evaluation (APACHE II) scores (response rate 50% vs. 68%, p 0.48, respectively), and
were also lower in patients with long-term (>20 days) vs. shorter duration (£20 days) neutropenia (55%
vs. 73%, p 0.32, respectively), and in those with an underlying haematological malignancy vs. patients
with other diseases (59% vs. 73%, p 0.2, respectively). In ﬁve (6%) patients, caspofungin therapy was
discontinued prematurely because of adverse drug reactions (ADRs) (elevated liver enzyme values in
three patients, neuropathic pain in one, and skin rash in one). Serious ADRs occurred in two (3%)
patients (severe hepatic insufﬁciency with consequent death, and eosinophilia with elevated alkaline
phosphatase levels), and laboratory abnormalities, mostly mild and reversible, in 24 (31%) patients. In
this unselected patient population, caspofungin was safe, well-tolerated, and had an efﬁcacy comparable
to that in previous reports from prospective trials.
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INTRODUCTION
The incidence of invasive fungal infection (IFI) has
increased substantially in recent decades. IFI-
related mortality rates vary from 20% to >95%,
depending on the type of fungal infection and
the underlying medical condition [1–7]. In a recent
study, cases of candidaemia increased in-hospital
mortality by 15% among adult patients, resulting
in a total in-hospital mortality rate of 31% [7]. The
mortality rate of invasive aspergillosis in solid
organ or haematological stem-cell transplant
patients is much higher, at 63–100% [8].
New antifungal drugs, such as echinocandins
(caspofungin) and new azoles (voriconazole,
posaconazole), have recently become available.
Caspofungin inhibits fungal cell-wall synthesis by
inhibiting production of b-1,3-D glucan, a com-
ponent of the fungal cell wall that is not present in
mammalian cells [9]. This mode of action is
distinct from that of azoles and polyenes [10].
Caspofungin has demonstrated favourable anti-
fungal activity in vitro against different Candida
spp., including azole-resistant isolates [11], and
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has been used in Finland since January 2001.
Caspofungin was initially approved for the treat-
ment of invasive aspergillosis that is refractory or
intolerant to amphotericin B, and later for the
empirical treatment of invasive candidiasis and
febrile neutropenia [12–14]. Few data are avail-
able concerning the use of caspofungin in patients
outside clinical studies in unselected patient
populations [15]. The aim of the present study
was to evaluate retrospectively the use of caspo-
fungin in Finland between January 2001 and
October 2004.
PATIENTS AND METHODS
This study was a retrospective, non-comparative, multicentre
clinical evaluation designed to estimate the efﬁcacy and safety
of caspofungin used for the treatment of IFI in Finland during
the period 2001–2004. Clinical proﬁles of the patients, as well
as response rates, proportion of premature discontinuations
and emergence of adverse drug reactions (ADRs), were
evaluated. The study was carried out in four Finnish univer-
sity hospitals (Helsinki, Turku, Kuopio and Oulu) and one
central hospital (Pa¨ija¨t-Ha¨me). All patients aged ‡16 years
who had been treated with caspofungin were included in the
study.
A retrospective review of the patients’ charts was per-
formed, and the data were collected on specially designed
forms. Each patient was assessed on the basis of data compiled
from medical records, radiology reports, laboratory and
microbiological analyses, surgical procedures, bronchoscopies
and autopsies. The data collected included demographical
variables, underlying diseases, risk-factors for IFI, indications
for caspofungin use, dosing, clinical response, laboratory
abnormalities and ADRs. Patients were stratiﬁed according
to the presence or absence of microbiological conﬁrmation of
IFI, aetiology of infection, Acute Physiology and Chronic
Health Evaluation (APACHE II) score, and the severity and
duration of neutropenia. All data were checked by the two
principal authors (V-J A, JS), and any uncertainties, lack of
information or disagreements were resolved in meetings.
An IFI was considered to be microbiologically proven on
the basis of the standard deﬁnitions published by the Invasive
Fungal Infections Cooperative Group of the European Organ-
ization for Research and Treatment of Cancer (EORTC) and the
Mycoses Study Group of the National Institute of Allergy and
Infectious Diseases [16].
The Ethical Committee of Internal Medicine at Helsinki
University Central Hospital approved the study protocol, and
the research was carried out in accordance with the Helsinki
Declaration.
Assessment of response
Predeﬁned response criteria were used for evaluation. A
favourable response was considered to be either a complete or
a partial clinical cure. Complete response was deﬁned as
resolution of all attributable clinical signs, symptoms and
radiological or bronchoscopic abnormalities, and partial
response as a clinically signiﬁcant improvement of the afore-
mentioned signs and symptoms. Treatment failure was
deﬁned as a deterioration of clinical condition or radio-
graphical abnormalities, necessitating a change of antifungal
therapy or resulting in the death of the patient. Relapse was
deﬁned as re-emergence of the IFI after discontinuation of
successful therapy [12,13].
Successful use of empirical caspofungin therapy was
deﬁned according to the modiﬁed criteria published by Walsh
et al. [17]. These criteria include the survival of the patient for
‡7 days after initiation of treatment, resolution of fever,
absence of breakthrough fungal infections during treatment,
and the absence of premature discontinuation of treatment
caused by ADRs or lack of efﬁcacy.
Assessment of safety and tolerability
For the safety assessment, all ADRs that were possibly related
to use of caspofungin were registered and reported. In
particular, signs of hepatotoxicity, nephrotoxicity and drug-
related laboratory abnormalities, as well as possible interac-
tions between caspofungin and cyclosporin A, were analysed.
The ADRs recorded from the medical records included chills,
hypotension, phlebitis, tachycardia, diarrhoea, nausea, vomit-
ing, tachypnoea, eczema, ﬂushing and headache. Laboratory
values, e.g., serum aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (ALP), bilirubin,
creatinine and potassium levels, and leukocyte, haemoglobin
and haematocrit counts, were also analysed. Nephrotoxicity
was deﬁned as a doubling of the normal baseline value
(£115 lmol ⁄L) of serum creatinine, or as an increase of an
elevated value by ‡1 mg ⁄dL (88 lmol ⁄L). Hepatotoxicity was
deﬁned as a concentration of AST or ALT that was ﬁve-fold
higher than the baseline value, provided that the baseline
value was less than twice the upper limit of normal (ALT and
AST 35 U ⁄L in females, 50 U ⁄L in males), more than three-fold
the baseline value if the baseline value was two- to ﬁve-fold
the upper limit of normal, and more than twice the baseline
value if the baseline value was ﬁve- to ten-fold the upper limit
of normal [14,17].
Statistical analysis
The chi-square test was used for comparisons of differences in
rates; p values <0.05 were regarded as statistically signiﬁcant.
RESULTS
Patient characteristics
Characteristics of the 78 patients evaluated in the
study are shown in Table 1. Caspofungin was
used for the treatment of microbiologically pro-
ven IFI in 59 (76%) patients (Table 2). Nineteen
(24%) patients received caspofungin empirically
for suspected IFI (Table 1). Thirteen (17%)
patients received caspofungin as primary therapy.
The remaining 65 (83%) patients had received one
or several other antifungal agents (amphotericin
B, ﬂuconazole, voriconazole, itraconazole) before
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caspofungin. Of these patients, 46 were refractory
to and 15 were intolerant of the preceding anti-
fungal medication, and caspofungin was given to
four patients to avoid potentially harmful inter-
actions with other drugs.
The mean (±SD) duration of caspofungin treat-
ment was 23 (±24) days (range 1–115 days).
Caspofungin therapy was started at a dose of
70 mg in 68 (87%) patients. The maintenance dose
was 50 mg in 70 (90%) patients. Eight (10%)
patients received other antifungal therapy con-
comitantly with caspofungin: three (4%) received
amphotericin B, four (5%) ﬂuconazole and one
(1%) ﬂucytocine.
Overall response
The response data were stratiﬁed according to the
aetiology of the infection, APACHE II scores,
underlying haematological malignancy, and the
severity and duration of neutropenia (Table 3). A
favourable response was achieved in 52 (67%)
patients. A complete response was achieved in 36
Table 1. Characteristics of patients (n = 78) treated with
caspofungin
Total
no. (%)
Candida
infections
n = 37
Aspergillus
infections
n = 22
Empirical
treatment
n = 19
Gender
Male 47 (60) 27 14 6
Female 31 (40) 10 8 13
Age, median years
(range)
55 (16–83) 58 (16–83) 51 (35–68) 58 (16–78)
Site of infection n (%)
Lung 20 (26) 4 16
Blood (candidaemia) 15 (19) 15 0
Abscess 10 (13) 10 0
Peritoneal ﬂuid 9 (12) 9 0
CNS 4 (5) 0 4
Skin 1 (1) 1 0
Other 21 (27) 16 5
Underlying disease
Haematological malignancy 37 (48) 13 13 11
Acute leukaemia 20 (26) 7 8 5
Lymphomaa 7 (9) 3 2 2
Chronic leukaemiaa 3 (4) 2 0 1
Myeloma 1 (1) 1 0 0
Other 7 (9) 0 3 4
Stem-cell transplantation 11 (14) 4 5 2
Allogeneic 9 (12) 3 4 2
Autologous 2 (3) 1 1 0
Diabetes 11 (14) 6 4 1
Autoimmune disease 11 (14) 4 4 3
Atherosclerotic vascular disease 9 (12) 6 2 1
Solid organ transplantation 6 (8) 3 1 2
Chronic pulmonary disease 4 (5) 1 2 1
Cancer 2 (3) 1 1 0
HIV 1 (1) 0 0 1
Renal insufﬁciency 21 (27) 9 6 6
Hepatic insufﬁciency 9 (12) 4 1 4
APACHE II score 23 (29) 12 2 9
£20 19 (24) 10 2 7
>20 4 (5) 2 0 2
Neutropeniab 26 (33) 9 9 8
Risk-factor for fungal infection
Broad-spectrum antibiotic use 66 (85) 33 15 18
Central venous line 51 (65) 30 9 12
Recent surgery 20 (26) 16 0 4
Use of corticosteroids 41 (53) 16 14 11
Previous antifungal therapyc
One antifungal agent 46 (59) 26 10 10
Two antifungal agents 14 (18) 5 5 4
Three antifungal agents 5 (6) 5 0 0
aOne patient had concomitant chronic lymphatic leukaemia and non-Hodgkin’s
lymphoma.
bAbsolute neutrophil count <500 ⁄ lL.
cAssessed 14 days before the start of caspofungin treatment.
APACHE, Acute Physiology and Chronic Health Evaluation; HIV, human immu-
nodeﬁciency virus; CNS, central nervous system.
Table 2. Microbiologically-proven invasive candidiasis
(n = 37) and aspergillosis (n = 22) in patients treated with
caspofungin n (%)
n (%)
Candidiasis 37 (47)
Candidaemia 15 (19)
Candida albicans 7 (9)
Candida glabrata 4 (5)
Candida krusei 3 (4)
C. albicans + Candida dubliniensis + C. glabrata 1 (1)
Candida peritonitisa 7 (9)
C. albicans 3
C. glabrata 3
C. krusei 2
Hepatosplenic candidiasis 3 (4)
C. albicans 1 (1)
Not speciﬁed 2 (3)
Pulmonary infectionb 4 (5)
C. albicans + C. krusei 2
C. albicans 1
C. krusei 1
Central venous catheter 2 (3)
C. albicans 1
Candida parapsilosis + Candida lusitanea 1
Bone 2 (3)
C. albicans 1
C. krusei 1
Other invasive candidiasisc 4 (5)
Aspergillosis 22 (28)
Pulmonary 16 (21)
Disseminated with CNS involvement 3 (4)
CNS only 1 (1)
Other (sinus, ear) 2 (3)
aOne patient had both C. albicans and C. krusei.
bTwo patients also had haematological dissemination of Candida, and the diagnosis
was conﬁrmed in two patients by autopsy (histology + culture).
cOne urine (C. glabrata), one mediastinitis (C. albicans), one oesophagitis (C. krusei),
one sinusitis (C. krusei).
CNS, central nervous system.
Table 3. Response rates in patients at the end of caspo-
fungin treatment (expressed as no. of patients with a
favourable response ⁄ total no. of patients in the group (%))
Invasive fungal infection 37 ⁄ 59 (63%) p 0.14
Aspergillosis 11 ⁄ 22 (50%)
Candidiasis 25 ⁄ 37 (68%)
Empirically treated infections 15 ⁄ 19 (79%)
APACHE II score p 0.48
£20 13 ⁄ 19 (68%)
>20 2 ⁄ 4 (50%)
Neutropeniaa p 0.87
No 35 ⁄ 52 (67%)
Yes 17 ⁄ 26 (65%)
Duration £20 days 11 ⁄ 15 (73%) p 0.32
Duration >20 days 6 ⁄ 11 (55%)
Haematological malignancy p 0.2
No 30 ⁄ 41 (73%)
Yes 22 ⁄ 37 (59%)
aAbsolute neutrophil count <500 ⁄ lL.
APACHE, Acute Physiology and Chronic Health Evaluation.
608 Clinical Microbiology and Infection, Volume 13 Number 6, June 2007
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 606–612
(46%) patients, and a partial response in 16 (21%)
patients. Seven (9%) patients had a stable out-
come at the end of treatment.
Treatment failed in 19 (24%) patients, nine of
whom had a haematological malignancy. A
relapse of the IFI occurred in seven (9%) patients
within 6 months following the cessation of caspo-
fungin therapy; the relapse occurred within
2 weeks post-treatment in four of the six patients.
At the end of the study period (October 2004), 40
(51%) patients remained alive. Of the 38 (49%)
deceased patients, eight (10%) died of fungal
infection (Table 4). Three of these eight patients
had a refractory haematological malignancy with
neutropenia, one had a severe graft vs. host
reaction, and one had leukaemia in remission.
Three patients had other underlying diseases, i.e.,
interstitial nephritis, endocarditis and pulmonary
ﬁbrosis. Ten (13%) patients died of other diseases
with fungal infection still persistent. In total, 26
patients (74% of all deceased patients) underwent
autopsy, and 18 (23%) patients had no signs of
fungal infection.
Safety and tolerability
ADRs and laboratory abnormalities. ADRs, probably
related to caspofungin treatment, were found in
four (5%) patients. One patient had chills and
fever on the ﬁrst day of treatment, one had a rash,
one had ﬂushing, and one had neuropathic pain,
probably caused by metronidazole given concom-
itantly with caspofungin. Drug-related laboratory
abnormalities occurred in 24 (31%) patients
(Table 5). In most patients, the laboratory values
were already abnormal before caspofungin treat-
ment. Most laboratory abnormalities were mild
and reversible. Elevated serum bilirubin, AST and
ALT levels returned to normal in one, two and
four patients, respectively, during caspofungin
therapy. Criteria for both nephrotoxicity and
hepatotoxicity were fulﬁlled in four (5%) patients.
Three patients with hepatotoxic signs had also
received other drugs (including asparaginase,
clonazepam, phenobarbital, phenytoin, clindamy-
cin and trimethoprim–sulphonamide), which
possibly predisposed them to liver toxicity. Alto-
gether, 20 (26%) patients received other hepato-
toxic drugs concomitantly with caspofungin. Two
patients with nephrotoxic signs had received
vancomycin or cyclosporin A. Aminoglycosides
or vancomycin were given to 16 (21%) and 26
(33%) patients, respectively.
Serious ADRs. Two (3%) patients were reported to
have serious ADRs (severe hepatic insufﬁciency
with consequent death, and eosinophilia with
elevated ALP).
A female student aged 20 years was treated in
an intensive care unit (ICU) for prolonged
Table 4. Outcome of patients with Candida and Aspergillus infections
No. of
patients Survived
Died of fungal
infection
Died of other disease,
fungal infection present
Died of other disease,
fungal infection absent
Candida infection 37 19 3 6 9
Haematological malignancy 13 5 1 5 2
Organ transplantation 3 1 1 1
Other disease 21 13 1 1 6
Aspergillus infection 22 10 5 4 3
Haematological malignancy 13 4 4 3 2
Organ transplantation 1 0 0 0 1
Other disease 8 6 1 1 0
Table 5. Drug-related laboratory abnormalities in patients
(n = 78) treated with caspofungin
No. (%) of
patientsa
Patients (%) with
abnormal value
before
caspofungin
therapy
Serum creatinineb › 8 (10.3) 4 ⁄ 8 (50)
Serum potassiumc ﬂ 6 (7.7) 1 ⁄ 6 (17)
Serum magnesiumd ﬂ 1 (1.3) 0 ⁄ 1 (0)
ALTe › 11 (14.1) 7 ⁄ 11 (64)
ASTf › 8 (10.3) 5 ⁄ 8 (63)
ALPg › 12 (15.4) 7 ⁄ 12 (58)
Bilirubinh › 7 (9.0) 6 ⁄ 7 (86)
Eosinophil counti › 1 (1.3) 0 ⁄ 1 (0)
aTwo patients with increased serum creatinine received vancomycin and cyclosp-
orin concomitantly with caspofungin, and three patients with increased liver
enzyme values received other hepatotoxic drugs concomitantly with caspofungin.
bIncreased serum creatinine was deﬁned as a concentration >115 lmol ⁄L.
cIncreased serum potassium was deﬁned as a concentration >5.1 mmol ⁄L.
dIncreased serum magnesium was deﬁned as a concentration >1.0 mmol ⁄L.
eALT, serum alanine aminotransferase; increased serum ALT was deﬁned as a
concentration >35 U ⁄L in females and >50 U ⁄L in males.
fAST, serum aspartate aminotransferase; increased serum AST was deﬁned as a
concentration >35 U ⁄L in females and >50 U ⁄L in males.
gALP, serum alkaline phosphatase; increased serum ALP was deﬁned as a
concentration >275 U ⁄L.
hIncreased bilirubin was deﬁned as a serum bilirubin concentration >20 lmol ⁄L.
iIncreased eosinophil count was deﬁned as a serum count >0.4 · 109 ⁄L.
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epileptic seizures. She developed candidaemia
(caused by Candida albicans), which did not
respond to ﬂuconazole. The patient received
caspofungin for 40 days (29 days at a reduced
dose of 35 mg ⁄day). For the ﬁrst 9 days, she
received conventional amphotericin B concomit-
antly with caspofungin. After discontinuation of
caspofungin, the patient developed severe hep-
atic insufﬁciency and died. An autopsy revealed
acute respiratory distress syndrome and hepatic
necrosis. The patient had received several hepa-
totoxic drugs (anti-epileptics) in the ICU, and
several antibiotics because of serious bacterial
infections, which could have contributed to the
hepatic injury. However, a possible relationship
with caspofungin treatment could not be ruled
out.
Another patient, a male aged 40 years with
acute lymphoblastic leukaemia, developed
invasive aspergillosis. He received caspofungin
for 69 days and the infection was cured. He
developed eosinophilia and elevated ALP values
during the late phase of caspofungin treatment,
but the laboratory values returned to normal after
discontinuation of caspofungin.
Discontinuations. ADRs and drug-related laborat-
ory abnormalities led to the discontinuation of
caspofungin therapy by ﬁve (6%) patients.
Elevated liver enzyme values were the reason
for withdrawal of caspofungin in three (4%)
patients. In one patient, caspofungin treatment
was stopped after 69 days because of elevated
ALP values, and in another patient after 18 days
because of elevated ALT values. In the third
patient, caspofungin was stopped after 16 days
because of both elevated bilirubin and ALT
values. The laboratory values returned to nor-
mal in all of these patients after withdrawal of
antifungal therapy, and the patients survived.
Caspofungin treatment was also discontinued
by two (3%) patients because of clinical ADRs.
One patient experienced neuropathic pain after
having received caspofungin concomitantly with
metronidazole for 101 days. Although the long-
term therapy with metronidazole was consid-
ered to be the most probable cause of the
neuropathy, caspofungin could not be ruled out
as the cause. Another patient developed a skin
rash after receiving caspofungin therapy for
3 days; the rash disappeared when caspofungin
was replaced by liposomal amphotericin B.
Concomitant use of caspofungin with cyclosporin A.
Five patients receiving cyclosporin A were given
caspofungin without any major clinical or labor-
atory adverse events.
DISCUSSION
The present study is the ﬁrst comprehensive
report of the use of caspofungin for the treatment
of IFI in Finland. The assessment of indications,
outcome and safety of caspofungin therapy was
based on the medical data for patients treated in
ﬁve major university or central hospitals in
Finland during the period 2001–2004. As these
ﬁve centres covered >90% of the nationwide use
of caspofungin during the study period, this
report gives a reliable account of the use of the
drug in an unselected patient population during
the early post-marketing period. The total number
of cases of IFI in Finland is unknown, as no
nationwide register of deep fungal infection
exists. However, cases of candidaemia are regis-
tered by the National Public Health Institute, with
640 cases being registered during 2001–2004.
Fifteen (2.3%) of these patients were treated with
caspofungin and were included in the present
study.
According to the present study, caspofungin
was mostly used as the second-, third- or fourth-
line drug in patients refractory to or intolerant of
conventional antifungal therapy. In addition to
serious IFI, half of the patients had a haemato-
logical malignancy, one-third had neutropenia,
and several had other severe underlying diseases.
In this seriously-ill patient population, the
achievement of a favourable response in 67% of
patients with IFI is remarkable. The response rate
achieved by caspofungin treatment was higher in
patients with candidiasis (78%) than in patients
with aspergillosis (50%). These results are com-
parable with the studies by Mora-Duarte et al.
[12], who reported a favourable response with
caspofungin in 73–81% of patients with candidi-
asis, and by Maertens et al. [13], who reported a
favourable outcome in 45% of patients with
aspergillosis.
It is generally agreed that empirical antifungal
treatment should be started if neutropenic
patients remain febrile following treatment for
4–7 days with broad-spectrum antibiotics [18].
Caspofungin has been shown to be equally
effective and generally better-tolerated than
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liposomal amphotericin B when given empirically
to neutropenic patients [14]. One-third of the
patients reviewed in the present study were
neutropenic (neutrophil count <500 ⁄ lL), but a
favourable response was achieved in 65% of
neutropenic and in 67% of non-neutropenic
patients. In the studies by Mora-Duarte et al.
[12] and Maertens et al. [13], the response rates
were dependent on the neutrophil counts of
patients.
As expected, the duration of neutropenia
appeared to affect adversely the outcome of
caspofungin therapy. A favourable outcome was
achieved in 73% of patients whose neutropenia
had lasted £20 days, and in only 55% of patients
with longer-term neutropenia. However, because
of the relatively low number of patients in these
groups, the outcome data for these patients
should be interpreted with caution. The small
number of individuals meant that the effect of
neutropenia on the response rates was not
assessed separately for patients with candidiasis
and aspergillosis. Patients with a haematological
malignancy had a less favourable response to
caspofungin than those without such a disease. In
particular, non-neutropenic haematological
patients had a poor prognosis; eight of 11 patients
died during follow-up. Nevertheless, most
patients responded favourably to caspofungin
therapy.
The advantages of caspofungin are its low renal
toxicity and its efﬁcacy against ﬂuconazole-resist-
ant Candida spp. Patients in an ICU with high
(>20) APACHE II scores tended to have a worse
response rate than those with lower scores.
The present retrospective study combined a
very heterogeneous patient population with a
variety of underlying diseases. The patients
received many antifungal treatments, and the
duration of the caspofungin treatment varied
greatly. Therefore, the data should be assessed
with some caution. An exact evaluation of the
efﬁcacy of caspofungin is limited because of the
design of this study. Nevertheless, the overall
response rate was consistent with ﬁndings report-
ed in previous controlled prospective studies.
Thus, caspofungin was safe and well-tolerated
when compared with the large trial involving 556
patients by Walsh et al. [14]. The frequency of
discontinuations because of ADRs was similar.
Concurrent use of caspofungin and cyclosporin is
not recommended because of the transient liver
enzyme elevations reported in healthy volunteers
[19]. However, the present study, as well as other
retrospective analyses, suggests that the risk of
clinically signiﬁcant hepatotoxicity is low [20,21].
In conclusion, the use of caspofungin in Finland
was found to be very controlled, and the indica-
tions for its use had been carefully selected in the
early post-marketing period. The good overall
response rate and favourable safety proﬁle of
caspofungin in this study are consistent with
ﬁndings reported previously. There is a need for
more prospective clinical studies on the use of
caspofungin in seriously-ill patients requiring
treatment in an ICU.
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